Sinar Mas provided $250m for Dana while Prosperity7 Ventures led a tranche that took Insilico’s series D round to $95m.
M&A
Precision medicine producer Gemini Therapeutics has agreed to merge with Disc Medicine, a US-based haematologic disease therapy developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, pharmaceutical firm Novo and conglomerate Access Industries. The combined entity will operate under the name Disc Medicine and take Gemini’s listing on the Nasdaq Global Market. It will have about $175m in cash when the transaction closes later this year, including $53.5m from existing Disc investors such as…
